CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...